Scarica l'app Stockscreener
3.56
2,185%
3.4042
Dopo l'orario di chiusura:
3.46
-0.10
-2.81%
Plus Therapeutics Inc Borsa (PSTV) Ultime notizie
Volume Report: Is Plus Therapeutics Inc a top pick in the sectorTrade Exit Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Plus Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | XMP1 | US72941H8060 - MarketScreener
Plus Therapeutics Inc (XMP0.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Plus Therapeutics: Financial Data Forecasts Estimates and Expectations | XMP0 | US72941H8060 - marketscreener.com
Plus Therapeutics: Target Price Consensus and Analysts Recommendations | XMP0 | US72941H8060 - MarketScreener
Plus Therapeutics Inc (FRA:XMP1) Stock Earnings Transcripts - GuruFocus
Tranche Update on Plus Therapeutics, Inc.'s Equity Buyback Plan announced on October 31, 2023. - MarketScreener
Plus Therapeutics: Revenue and Earnings Analysts Forecasts Revisions | XMP0 | US72941H8060 - MarketScreener
Plus Therapeutics Inc Stock Operating Data - GuruFocus
Plus Therapeutics Inc (FRA:XMP1) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Plus Therapeutics Inc (FRA:XMP1) Stock Price & 30 Year Financial Data - GuruFocus
Plus Therapeutics Inc (FRA:XMP1) Stock News, Headlines & Updates - GuruFocus
Plus Therapeutics Inc (FRA:XMP1) Stock Price, Trades & News - GuruFocus
Plus Therapeutics: Dividend historical data and projections - MarketScreener
Plus Therapeutics Enacts Reverse Stock Split to Maintain Listing - TipRanks
Reverse split shrinks Plus Therapeutics (NASDAQ: PSTV) share count to 6.9M - Stock Titan
Plus Therapeutics (NASDAQ:PSTV) Stock Price Down 9.9%Here's Why - MarketBeat
Plus Therapeutics Expands Reimbursement for CNSide® CSF Assay to 75 Million Covered Lives - National Today
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives - manilatimes.net
PSTV Stock Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
Plus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Sims Andrew John Hugh MacIntyremoomoo - Moomoo
Plus Therapeutics (PSTV) CFO acquires 67,452 shares through RSU vesting - Stock Titan
Plus Therapeutics (PSTV) CEO exercises 361,313 RSUs into stock - Stock Titan
Plus Therapeutics Inc. (NASDAQ:PSTV) - intelligentinvestor.com.au
Plus Therapeutics approves 1-for-25 reverse stock split By Investing.com - au.investing.com
Plus Therapeutics, Inc. Announces 1-for-25 Reverse Stock Split Effective April 2, 2026 - Moomoo
Plus Therapeutics | DEF 14A: Definitive information statements - moomoo.com
Published on: 2026-04-01 11:00:22 - baoquankhu1.vn
Plus Therapeutics To Carry Out 1-for-25 Reverse Stock Split On April 2nd, 2026 - Moomoo
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Plus Therapeutics Approves 1-for-25 Reverse Stock Split - Intellectia AI
[ARS] PLUS THERAPEUTICS, INC. SEC Filing - Stock Titan
Plus Therapeutics (NASDAQ: PSTV) sets 2026 virtual meeting, executive pay and equity plan vote - Stock Titan
Plus Therapeutics announces 1-for-25 reverse stock split - MSN
This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For TuesdayCentessa P - Benzinga
Plus Therapeutics (PSTV) Downgraded to Hold by D. Boral Capital - GuruFocus
Plus Therapeutics Announces Reverse Stock Split - Bitget
D. Boral Capital downgrades Plus Therapeutics stock rating on reverse split By Investing.com - Investing.com South Africa
D. Boral Capital downgrades Plus Therapeutics stock rating on reverse split - Investing.com
Plus Therapeutics approves 1-for-25 reverse stock split - Investing.com
Plus Therapeutics announces reverse stock split - MarketScreener
PLUS THERAPEUTICS (PSTV) director files Form 3 with zero shares - Stock Titan
PSTV Stock Price, Quote & Chart | PLUS THERAPEUTICS INC (NASDAQ:PSTV) - ChartMill
PLUS THERAPEUTICS, INC. Files Form 8-K Current Report with SEC – Company Details, Address, and Compliance Information 18 - Minichart
Plus Therapeutics Appoints Ron Andrews to Board - Intellectia AI
Plus Therapeutics appoints Ronald A. Andrews to board following director resignation By Investing.com - Investing.com South Africa
Plus Therapeutics Adds Industry Veteran Ronald Andrews to Board - TipRanks
Plus Therapeutics appoints Ronald A. Andrews to board following director resignation - Investing.com
Plus appoints Ronald A. Andrews to Board as Robert Lenk resigns - TradingView
Ronald Andrews joins Plus Therapeutics (NASDAQ: PSTV) board - Stock Titan
Plus Therapeutics appoints Ron Andrews to board of directors By Investing.com - Investing.com India
Plus Therapeutics appoints Ron Andrews to board of directors - Investing.com
Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors - The Manila Times
Plus Therapeutics Appoints Diagnostics and Molecular - GlobeNewswire
Aug Action: Will Plus Therapeutics Inc benefit from rising consumer demandPortfolio Return Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):